secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2026-10-08T21:23:01+00:00
Accession:  0001501697-26-000081
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 1.02, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

X4 Pharma secures up to $150M K2 HealthVentures loan; repays $78.7M Hercules debt, interest-only to Oct 2029
--------------------------------------------------------------------------------

- $80M first tranche funded at closing repaid Hercules' ~$78.7M payoff ($75M principal, interest, end-of-term and prepayment charges); up to $70M second tranche needs K2HV approval.
- Term loans bear interest at the greater of 8.55% or WSJ prime +1.55%, plus 1.0% paid-in-kind interest; interest-only through Oct 1, 2029, maturing Oct 1, 2030.
- Interest-only period extends to maturity if X4 achieves first U.S. commercial sales of mavorixafor in moderate to severe chronic neutropenia; K2HV may convert up to $15M into stock at $3.2341.
- Covenants from Oct 1, 2027: if market cap <$800M, unrestricted cash must cover 75% of obligations (40% after conditions); from Apr 1, 2029, trailing 3-month revenue ≥50% of board projections.
- X4 expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026 with topline data in H1 2028; loan is secured by substantially all assets excluding intellectual property.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/0001501697-26-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/xfor-20261007.htm
  HTML page:      https://secwatch.observer/filing/0001501697-26-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer